Novo Nordisk’s TBL Explorer

  • Novo Nordisk’s TBL Explorer
  • Novo Nordisk’s TBL Explorer
  • Novo Nordisk’s TBL Explorer
  • Novo Nordisk’s TBL Explorer

Detailed App Info:

  • Last Changed:Time:
  • Current Version:Version: 1.0
  • Device Type:Device: iPad Ready
  • Category:Category: Business
  • iTunes Seller:Seller:
  • Download Size:App Size: 393.23 MB

Application Description

Twitter:
Google:
Facebook:
Novo Nordisk’s Triple Bottom Line Explorer gives you an thorough understanding of the company’s approach to sustainability. The app introduces you to Novo Nordisk’s Triple Bottom Line (TBL) business principle and the initiatives and programmes that drive the company’s financial, social and environmental responsibility. The strategic commitment to corporate sustainability has brought the company onto centre stage as a leading player in today's business environment, recognised for its consistently high sustainability performance. For more information, please visit www.novonordisk.com/sustainability

This is the first version of Triple Bottom Line Explorer and we welcome your feed-back. Does it meet your information needs? Is it comprehensible? Is it user-friendly? You can let us know by sending an email to sustainability@novonordisk.com

Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 34,700 employees in 75 countries, and markets its products in more than 180 countries.

Requirements

Your mobile device must have at least 393.23 MB of space to download and install Novo Nordisk’s TBL Explorer app. Novo Nordisk’s TBL Explorer is available on iTunes for $0.00

If you have any problems with installation or in-app purchase, found bugs, questions, comments about this application, you can visit the official website of Novo Nordisk A/S at http://www.novonordisk.com/sustainability.

Copyright © Novo Nordisk A/S